RecruitingMigraine Disorders
EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.
Eligible age
18–75 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.
Sponsor: IRCCS San Raffaele Roma
Source: ClinicalTrials.gov · NCT05570149 · last updated 2025-05-01